Apellis Pharmaceuticals (NASDAQ:APLS) has received diverse analyst ratings over the past quarter, with a total of 14 analysts offering opinions ranging from bullish to bearish. The recent ratings show a shift towards more positive sentiment in the last 30 days. The 12-month price targets for APLS have an average of $79.43, with a high of $92.00 and a low of $60.00, marking a 13.47% increase from the previous average target of $70.00. Analysts have maintained or raised their ratings and price targets, reflecting changing market dynamics and Apellis Pharmaceuticals' performance. The company, a commercial-stage biopharmaceutical entity, focuses on novel therapies for diseases with high unmet needs. Despite its exceptional revenue growth rate of 545.89% over the past 3 months and a strong net margin of -60.51%, Apellis faces challenges with below-industry-average ROE and ROA, and a prudent debt management strategy with a debt-to-equity ratio of 0.57.